Search

Your search keyword '"Alessandra Lombardo"' showing total 5 results
Start Over Author "Alessandra Lombardo" Topic humans
5 results on '"Alessandra Lombardo"'

1. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials

Author

Antonella Bruzzese, Daniele Derudas, Monica Galli, Enrica Antonia Martino, Stefano Rocco, Concetta Conticello, Catello Califano, Nicola Giuliani, Silvia Mangiacavalli, Giuliana Farina, Alessandra Lombardo, Marino Brunori, Elena Rossi, Elisabetta Antonioli, Roberto Ria, Renato Zambello, Nicola Di Renzo, Giuseppe Mele, Gianpaolo Marcacci, Giuseppe Pietrantuono, Gaetano Palumbo, Nicola Cascavilla, Claudio Cerchione, Angelo Belotti, Clelia Criscuolo, Giuseppina Uccello, Paola Curci, Ernesto Vigna, Francesco Mendicino, Enrico Iaccino, Selena Mimmi, Cirino Botta, Donatella Vincelli, Nicola Sgherza, Angela Bonalumi, Luca Cupelli, Raffaella Stocchi, Massimo Martino, Stelvio Ballanti, Dominella Gangemi, Alfredo Gagliardi, Barbara Gamberi, Alessandra Pompa, Giovanni Tripepi, Ferdinando Frigeri, Ugo Consoli, Sara Bringhen, Elena Zamagni, Francesca Patriarca, Valerio De Stefano, Francesco Di Raimondo, Salvatore Palmieri, Maria Teresa Petrucci, Massimo Offidani, Pellegrino Musto, Mario Boccadoro, Michele Cavo, Antonino Neri, Fortunato Morabito, Massimo Gentile, Bruzzese, Antonella, Derudas, Daniele, Galli, Monica, Martino, Enrica Antonia, Rocco, Stefano, Conticello, Concetta, Califano, Catello, Giuliani, Nicola, Mangiacavalli, Silvia, Farina, Giuliana, Lombardo, Alessandra, Brunori, Marino, Rossi, Elena, Antonioli, Elisabetta, Ria, Roberto, Zambello, Renato, Di Renzo, Nicola, Mele, Giuseppe, Marcacci, Gianpaolo, Pietrantuono, Giuseppe, Palumbo, Gaetano, Cascavilla, Nicola, Cerchione, Claudio, Belotti, Angelo, Criscuolo, Clelia, Uccello, Giuseppina, Curci, Paola, Vigna, Ernesto, Mendicino, Francesco, Iaccino, Enrico, Mimmi, Selena, Botta, Cirino, Vincelli, Donatella, Sgherza, Nicola, Bonalumi, Angela, Cupelli, Luca, Stocchi, Raffaella, Martino, Massimo, Ballanti, Stelvio, Gangemi, Dominella, Gagliardi, Alfredo, Gamberi, Barbara, Pompa, Alessandra, Tripepi, Giovanni, Frigeri, Ferdinando, Consoli, Ugo, Bringhen, Sara, Zamagni, Elena, Patriarca, Francesca, De Stefano, Valerio, Di Raimondo, Francesco, Palmieri, Salvatore, Petrucci, Maria Teresa, Offidani, Massimo, Musto, Pellegrino, Boccadoro, Mario, Cavo, Michele, Neri, Antonino, Morabito, Fortunato, and Gentile, Massimo

Subjects
Cancer Research, lenalidomide, dexamethasone, elotuzumab, multiple myeloma, salvage therapy, Hematology, General Medicine, Antibodies, Monoclonal, Humanized, Thalidomide, Oncology, Antineoplastic Combined Chemotherapy Protocols, Humans, Settore MED/15 - Malattie del Sangue, Follow-Up Studies, Retrospective Studies
Abstract

The combination of elotuzumab, lenalidomide, and dexamethasone (EloRd) enhanced the clinical benefit over Rd with a manageable toxicity profile in the ELOQUENT-2 trial, leading to its approval in relapsed/refractory multiple myeloma (RRMM). The present study is a 3-year follow-up update of a previously published Italian real-life RRMM cohort of patients treated with EloRd. This revised analysis entered 319 RRMM patients accrued in 41 Italian centers. After a median follow-up of 36 months (range 6-55), 236 patients experienced disease progression or died. Median progression-free survival (PFS) and overall survival (OS) were 18.4 and 34 months, respectively. The updated multivariate analyses showed a significant reduction of PFS and OS benefit magnitude only in cases with ISS stage III. Major adverse events included grade 3/4 neutropenia (18.5%), anemia (15.4%), lymphocytopenia (12.5%), and thrombocytopenia (10.7%), while infection rates and pneumonia were 33.9% and 18.9%, respectively. No new safety signals with longer follow-up have been observed. Of 319 patients, 245 (76.7%) reached at least a partial remission. A significantly lower response rate was found in patients previously exposed to lenalidomide. In conclusion, our study confirms that EloRd is a safe and effective regimen for RRMM patients, maintaining benefits across multiple unfavorable subgroups. This article is protected by copyright. All rights reserved.

Published
2022
Full Text
View/download PDF

2. Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials

Author

Nicola Cascavilla, Monica Galli, Mario Boccadoro, Dominella Gangemi, Silvia Mangiacavalli, Massimo Offidani, Anna Grazia Recchia, Elena Zamagni, Angelo Belotti, Alessandra Pompa, Claudio Cerchione, Giuseppina Uccello, Paola Curci, Catello Califano, Concetta Conticello, Elena Rossi, Maria Teresa Petrucci, Valerio De Stefano, Giovanni Tripepi, Ugo Consoli, Enrico Attingenti, Marino Brunori, Stelvio Ballanti, Clelia Criscuolo, Nicola Giuliani, Michele Cavo, Renato Zambello, Vincenzo Ludovico Fraticelli, Giorgina Specchia, Angela Bonalumi, Francesca Patriarca, Nicola Di Renzo, Alessandra Lombardo, Salvatore Palmieri, Elisabetta Antonioli, Cirino Botta, Agostina Siniscalchi, Raffaella Stocchi, Barbara Gamberi, Ferdinando Frigeri, Massimo Gentile, Giuseppe Mele, Ernesto Vigna, Pellegrino Musto, Donatella Vincelli, Silvana Capalbo, Annalisa Pitino, Sara Bringhen, Daniele Derudas, Francesco Di Raimondo, Massimo Martino, Roberto Ria, Alfredo Gagliardi, Gianpaolo Marcacci, Fortunato Morabito, Stefano Rocco, Gentile M., Specchia G., Derudas D., Galli M., Botta C., Rocco S., Conticello C., Califano C., Giuliani N., Mangiacavalli S., Attingenti E., Lombardo A., Brunori M., Rossi E., Antonioli E., Ria R., Zambello R., Di Renzo N., Mele G., Marcacci G., Musto P., Capalbo S., Cascavilla N., Cerchione C., Belotti A., Criscuolo C., Uccello G., Curci P., Vigna E., Fraticelli V., Vincelli D., Bonalumi A., Siniscalchi A., Stocchi R., Martino M., Ballanti S., Gangemi D., Gagliardi A., Gamberi B., Pompa A., Recchia A.G., Tripepi G., Pitino A., Frigeri F., Consoli U., Bringhen S., Zamagni E., Patriarca F., De Stefano V., Di Raimondo F., Palmieri S., Petrucci M.T., Offidani M., Boccadoro M., Cavo M., and Morabito F.

Subjects
Oncology, medicine.medical_specialty, Elotuzumab, lenalidomide, dexamethasone, salvage therapy, multiple myeloma, Salvage therapy, Antibodies, Monoclonal, Humanized, Antibodies, Dexamethasone, Efficacy, Internal medicine, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Progression-free survival, Elotuzumab, Letters to the Editor, Elotuzumab, lenalidomide, dexamethasone, multiple myeloma, Humanized, Lenalidomide, Multiple myeloma, Retrospective Studies, Salvage Therapy, business.industry, Retrospective cohort study, Hematology, medicine.disease, Clinical trial, Italy, Multiple Myeloma, business, medicine.drug
Abstract

No abstract available

Published
2021

3. Huge mass of the scalp: Follicular lymphoma with complete regression after therapy

Author

Maurizio Zizzo, Magda Zanelli, Stefano Ascani, Valerio Annessi, Giovanni Martino, Alessandra Lombardo, and Francesca Sanguedolce

Subjects
medicine.medical_specialty, Scalp, Skin Neoplasms, business.industry, MEDLINE, Follicular lymphoma, Dermatology, General Medicine, medicine.disease, medicine.anatomical_structure, Complete regression, Humans, Medicine, Radiology, business, Lymphoma, Follicular
Published
2020
Full Text
View/download PDF

4. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study

Author

Stefano Spada, Mario Boccadoro, Roberto Mina, Angelo Belotti, Giuseppe Rossi, Lorenzo De Paoli, Rossella Troia, Antonio Palumbo, Alessandra Lombardo, Anna Marina Liberati, Sara Bringhen, Anna Maria Cafro, Pieter Sonneveld, Francesca Patriarca, Renato Fanin, Gianluca Gaidano, Paola Bertazzoni, and Hematology

Subjects
Oncology, medicine.medical_specialty, Cancer Research, Dexamethasone, Cohort Studies, 03 medical and health sciences, chemistry.chemical_compound, 0302 clinical medicine, Hematology, Anesthesiology and Pain Medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Survival rate, Multiple myeloma, business.industry, Low dose, Follow-Up Studies, Multiple Myeloma, Oligopeptides, Prognosis, Survival Rate, Thalidomide, medicine.disease, Pomalidomide, Carfilzomib, chemistry, 030220 oncology & carcinogenesis, Relapsed refractory, business, 030215 immunology, medicine.drug
Published
2017

5. Intracranial pressure after subarachnoid hemorrhage

Author

Angelo Colombo, Elisa R. Zanier, Alessandra Lombardo, Paolo Rampini, Tommaso Zoerle, Luca Longhi, and Nino Stocchetti

Subjects
Male, Subarachnoid hemorrhage, Intracranial Pressure, business.industry, Glasgow Outcome Scale, Brain, Neuroimaging, Middle Aged, Subarachnoid Hemorrhage, Critical Care and Intensive Care Medicine, medicine.disease, Article, Risk Factors, Anesthesia, Medicine, Humans, Female, cardiovascular diseases, Prospective Studies, Intracranial Hypertension, business, Tomography, X-Ray Computed, Intracranial pressure
Abstract

To describe mean intracranial pressure after aneurysmal subarachnoid hemorrhage, to identify clinical factors associated with increased mean intracranial pressure, and to explore the relationship between mean intracranial pressure and outcome.Analysis of a prospectively collected observational database.Neuroscience ICU of an academic hospital.One hundred sixteen patients with subarachnoid hemorrhage and intracranial pressure monitoring.None.Episodes of intracranial pressure greater than 20 mm Hg lasting at least 5 minutes and the mean intracranial pressure for every 12-hour interval were analyzed. The highest mean intracranial pressure was analyzed in relation to demographic characteristics, acute neurologic status, initial radiological findings, aneurysm treatment, clinical vasospasm, and ischemic lesion. Mortality and 6-month outcome (evaluated using a dichotomized Glasgow Outcome Scale) were also introduced in multivariable logistic models. Eighty-one percent of patients had at least one episode of high intracranial pressure and 36% had a highest mean intracranial pressure more than 20 mm Hg. The number of patients with high intracranial pressure peaked 3 days after subarachnoid hemorrhage and declined after day 7. Highest mean intracranial pressure greater than 20 mm Hg was significantly associated with initial neurologic status, aneurysmal rebleeding, amount of blood on CT scan, and ischemic lesion within 72 hours from subarachnoid hemorrhage. Patients with highest mean intracranial pressure greater than 20 mm Hg had significantly higher mortality. When death, vegetative state, and severe disability at 6 months were pooled, however, intracranial pressure was not an independent predictor of unfavorable outcome.High intracranial pressure is a common complication in the first week after subarachnoid hemorrhage in severe cases admitted to ICU. Mean intracranial pressure is associated with the severity of early brain injury and with mortality.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results